Time and Distance Cost of Longer Acting Anti-VEGF Therapies for Macular Degeneration: Contributions to Drug Cost Comparisons.

Elana A MeerDennis H OhFrank L Brodie

Published in: Clinical ophthalmology (Auckland, N.Z.) (2022)

Longer acting anti-VEGF therapies may differ not only in their wholesale acquisition cost, but also in the frequency of per label injections and associated clinic visits. Taking into account distance and time cost of travel may contribute to a more holistic view of cost differences among these therapies.

Keyphrases

endothelial cells
vascular endothelial growth factor
primary care
optical coherence tomography
diabetic retinopathy
platelet rich plasma
adverse drug